The FDA's advisory committee meets Thursday and Friday, and the questions came in fast. Here are the ones that came up most — the honest version, the same answer I'd give you across the desk. Where the truthful answer is "watch and wait," that's the answer you'll get.
No — and I want to be precise about why. What happens July 23–24 is a committee recommendation, not a rule. Even after the votes are recorded, the FDA would have to publish a proposed rule, open a second public comment period, and then issue a final rule before any peptide's durable status under the 503A framework actually changes. That path routinely takes more than a year.
So whatever the headlines say Thursday night, nothing on your protocol changes on the day of the vote. We already put our position on the public record — our physician comment was filed back in May.
Skip the doom-scroll. We keep one physician-updated page — the PCAC Watch tracker — with a live results table for both days and a plain-language read of each vote, posted within 48 hours of each session. One page, no spin.
And the part that matters most: if any outcome ever affects a specific therapy on your protocol, I contact you directly with a plan before anything changes. You will never learn about a change to your own care from a news headline.
Because sourcing is the entire safety story, and it's exactly what this FDA review is about. At Limitless I prescribe only what is lawfully compoundable under current categorization, dispensed through licensed 503A or 503B pharmacies with per-lot certificate-of-analysis and stability documentation.
The online "research-grade" market has none of that — unknown purity, no sterility guarantee, no dosing oversight, and in some cases suppliers with genuinely alarming histories. The price gap is real. So is the reason for it. I'd rather you pay for the oversight than gamble without it.
Not necessarily, and this is where careful reading matters. FDA's own briefing documents going into this meeting read skeptical on all seven substances — largely because the human evidence for many of them is early and thin, which is a different statement than "proven dangerous." An unfavorable vote would reflect that evidentiary gap, and it still wouldn't change the law overnight.
My job is to prescribe to the evidence and to your specific situation, name the uncertainty out loud, and adjust if the picture changes. That posture doesn't move with the news cycle. For the longer version, I wrote where compounded peptides stand in 2026.
No — your FDA-approved therapies are not part of this review at all. The July meeting is specifically about certain compounded peptide bulk substances being considered for the 503A bulks list. Testosterone and tesamorelin are approved medications and sit entirely outside it.
If you're an area patient trying to sort out what any of this means for your own plan, that's a conversation, not a headline — book a consult or read the local breakdown for Dalton & Chattanooga patients.
— Joshua Hare, DO, founder, Limitless Performance Medicine